United States

People: Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

22 Feb 2019
Change (% chg)

$0.38 (+2.11%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Given, Douglass 

Dr. Douglass B. Given M.D., Ph.D., is the Chairman of the Board and Director of Arrowhead Pharmaceuticals Inc. Dr. Given is the founder and managing partner of G5 Partners LLC and Director and Chief Executive Officer of Health 2047, Inc., a San Francisco, California based health information start up. Dr. Given joined Bay City Capital, LLC in 2000, served as a General Partner and Investment Partner from 2004-2014 and participated in more than 50 investments. Dr. Given has co-founded 14 startup companies. Dr. Given formerly held positions as Corporate Senior Vice President and Chief Technology Officer at Mallinckrodt, Vice President at Schering Plough, Vice President at Monsanto/GD Searle and Medical Advisor at Lilly. Dr. Given has been a Director at 8 public and 8 private companies and is currently Chairman at Arrowhead, Vivaldi Biosciences Inc. and Medical eXellence Inc. Dr. Given has held positions as CEO at Progenitor Inc, Mercator Genetics Inc, NeoRx Corp, VIA Pharmaceuticals Inc., and Vivaldi Biosciences Inc. Dr. Given has been a member of the University of Chicago Medical Center and Pritzker School of Medicine Visiting Committee since 1995 and served as its Chair from 2007-2013. Additional University of Chicago activities include the Center for Global Health External Advisory Board and Investment Committee for the Innovation Fund. Dr. Given is a member of the Johns Hopkins Bloomberg School of Public Health Advisory Board and its Development Committee and Innovation and Commercialization Committee. Dr. Given is a member of the Harvard School of Public Health International Advisory Council and the Stanford Medicine Community Council. Dr. Given received his MD & PhD from the University of Chicago and MBA from the Wharton School, University of Pennsylvania.

Basic Compensation

Total Annual Compensation, USD 77,813
Restricted Stock Awards, USD 124,000
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 201,813

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Douglass Given


Christopher Anzalone


Kenneth Myszkowski


Bruce Given


Patrick O'Brien


Michael Perry

As Of  29 Sep 2017